Share This Page
Drug Price Trends for NDC 16571-0411
✉ Email this page to a colleague
Average Pharmacy Cost for 16571-0411
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CIPROFLOXACIN HCL 250 MG TAB | 16571-0411-10 | 0.08855 | EACH | 2026-03-18 |
| CIPROFLOXACIN HCL 250 MG TAB | 16571-0411-10 | 0.08713 | EACH | 2026-02-18 |
| CIPROFLOXACIN HCL 250 MG TAB | 16571-0411-10 | 0.08817 | EACH | 2026-01-21 |
| CIPROFLOXACIN HCL 250 MG TAB | 16571-0411-10 | 0.08886 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 16571-0411
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Dynamics and Price Forecast for Nitisinone (NDC 16571-0411)
Nitisinone, identified by NDC 16571-0411 and marketed under brand names including Orfadin, is a tyrosine aminotransferase inhibitor used for the treatment of hereditary tyrosinemia type 1 (HT-1). This rare genetic disorder leads to the accumulation of toxic metabolites, causing severe liver and kidney damage. Nitisinone functions by inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD), an enzyme upstream in the tyrosine catabolic pathway, thereby reducing the production of these harmful substances. The market for nitisinone is characterized by its orphan drug status, a limited patient population, and a single primary competitor. Pricing is a critical factor due to the high cost of rare disease therapies and the ongoing need for long-term treatment.
What is the Current Market Landscape for Nitisinone?
The market for nitisinone (NDC 16571-0411) is defined by its designation as an orphan drug, which provides market exclusivity and incentives for development. The primary indication is HT-1, a condition affecting an estimated 1 in 100,000 live births globally. This limited patient pool necessitates specialized manufacturing and distribution. The dominant product in this market is Orfadin, manufactured by Sobi (Swedish Orphan Biovitrum AB).
The therapeutic landscape for HT-1 has significantly improved with the introduction of nitisinone, transforming it from a fatal condition with limited treatment options to a manageable chronic disease for many patients. Prior to nitisinone, liver transplantation was often the only definitive treatment for severe cases. The drug's efficacy in preventing the development of severe hepatic and renal complications has solidified its position as a standard of care.
Competition within the nitisinone market is presently minimal. The primary direct competitor is NITYR, a generic version of nitisinone approved and marketed by the U.S. Food and Drug Administration (FDA). The introduction of NITYR by its manufacturer, Zamys, has introduced a price competition dynamic that was previously absent with only the branded product available. This development is significant for payers and patients seeking cost-effective treatment options.
Key Market Factors:
- Orphan Drug Status: Nitisinone benefits from regulatory incentives, including market exclusivity and tax credits, designed to encourage the development of treatments for rare diseases. In the United States, orphan drug exclusivity typically lasts for seven years from approval for a new chemical entity.
- Limited Patient Population: The rarity of HT-1 dictates a small, specialized market. This impacts manufacturing volumes and the overall market size.
- Single Branded Product (Historically): For many years, Orfadin was the sole nitisinone therapy available, allowing for premium pricing.
- Emergence of Generic Competition: The approval and launch of NITYR have introduced a direct competitor, leading to price reductions and increased market access discussions.
- Long-Term Treatment Requirement: HT-1 is a chronic condition requiring lifelong treatment with nitisinone, ensuring sustained demand for approved therapies.
- High Cost of Therapy: As with many rare disease treatments, nitisinone therapies are expensive, with significant annual treatment costs per patient.
- Global Reach: While the patient population is small, HT-1 is a global condition, requiring distribution networks capable of reaching patients in various countries.
How Does the Emergence of Generic Nitisinone Impact Pricing?
The introduction of generic nitisinone (NITYR) by Zamys has initiated a significant price recalibration in the market for NDC 16571-0411. Historically, Orfadin commanded a premium price due to its orphan drug status and lack of direct competition. The launch of a generic alternative directly challenges this pricing structure.
Orfadin's average wholesale price (AWP) has historically been in the range of \$30,000 to \$40,000 per month for a typical pediatric dose, translating to annual costs exceeding \$360,000 to \$480,000 per patient. This high cost has been a substantial burden for healthcare systems and patients.
NITYR entered the market with a stated intention to offer a significantly lower price. Early reports and pricing indications suggest that NITYR's price point is approximately 30-50% lower than Orfadin's AWP. For instance, if Orfadin's monthly cost was \$35,000, NITYR might be priced around \$17,500 to \$24,500 per month. This represents a potential annual saving of tens of thousands of dollars per patient.
The competitive pricing strategies employed by NITYR are likely to force further price adjustments from Sobi for Orfadin to remain competitive, particularly in markets where price is a significant determinant of formulary placement and patient access. Payers, including insurance companies and government health programs, are expected to favor the lower-cost generic option, driving prescription volume towards NITYR.
Pricing Impact Analysis:
- Orfadin (Branded Nitisinone): Pre-generic pricing was characterized by high annual costs, estimated between \$360,000 and \$480,000 per patient.
- NITYR (Generic Nitisinone): Launched with a target price 30-50% lower than Orfadin, potentially reducing annual costs to \$210,000 - \$340,000 per patient.
- Market Share Shift: Payers are anticipated to favor NITYR, leading to a gradual shift in market share away from Orfadin.
- Price Erosion: The presence of a generic is expected to cause sustained price erosion for both products over time, though branded products often maintain a premium.
- Negotiation Leverage: Payers and hospital systems will have increased negotiation leverage with both Sobi and Zamys.
What are the Projected Price Trends for Nitisinone in the Next Five Years?
The price trajectory for nitisinone (NDC 16571-0411) over the next five years will be predominantly influenced by the ongoing competition between the branded product (Orfadin) and its generic counterpart (NITYR). Several factors will shape these trends.
The initial aggressive pricing of NITYR will likely set a new benchmark. While branded drugs in rare disease markets can command premium pricing, the presence of a lower-cost generic will exert downward pressure. It is probable that Sobi will adjust its pricing strategy for Orfadin to compete with NITYR, potentially offering volume discounts or rebates to maintain market share, especially with large institutional purchasers or within specific healthcare systems.
We anticipate a gradual decrease in the average selling price (ASP) for nitisinone overall. The initial discount offered by NITYR is substantial, and as more payers adopt the generic, its market penetration will increase. This will, in turn, encourage further price competition.
Projected Price Trends (5-Year Outlook):
- Year 1-2: Significant price reduction driven by NITYR's market entry. Orfadin price may see a reduction of 20-30% to remain competitive. NITYR price is expected to stabilize after initial launch fluctuations.
- Year 3-4: Continued price erosion. As NITYR gains more market share, payer negotiations will become more aggressive, potentially driving down prices by an additional 10-15% for both products.
- Year 5: Prices may stabilize at a new, lower equilibrium. The rate of erosion will likely slow as the market adapts to the competitive landscape. Further price reductions will be more incremental, driven by gross-to-net adjustments and specific payer contracts.
Specific Projections:
- Orfadin ASP: Projected to decrease by 30-45% from its pre-generic peak within five years.
- NITYR ASP: Projected to decrease by 10-20% from its initial launch price within five years, primarily due to competitive pressures and volume discounts.
- Overall Market ASP: The average ASP for nitisinone is projected to decline by approximately 30-50% from pre-generic levels within five years.
This downward trend is not absolute; factors such as manufacturing costs, supply chain complexities, and the potential for new indications or formulations could influence future pricing. However, the immediate and foreseeable future is marked by increased affordability driven by generic competition.
What is the Patient Access and Reimbursement Outlook?
Patient access to nitisinone (NDC 16571-0411) is heavily reliant on reimbursement structures and payer policies, particularly given the high cost of the therapy. The introduction of a generic alternative, NITYR, is expected to improve access by reducing the financial burden on patients and healthcare systems.
Historically, patients with HT-1 have relied on a combination of private insurance, Medicaid, and patient assistance programs (PAPs) to cover the costs of Orfadin. The drug's high price has often led to significant out-of-pocket expenses for patients, even with comprehensive insurance coverage, and has sometimes necessitated appeals to secure coverage.
With the availability of NITYR, payers are likely to implement more favorable coverage policies for nitisinone therapy overall. Insurers are generally motivated to cover orphan drugs when medically necessary, but the price difference will be a major factor. NITYR's lower cost will make it a more straightforward formulary inclusion for many plans, reducing the likelihood of prior authorization denials or step-therapy requirements that could delay treatment initiation.
For patients, the reduced co-pays and deductibles associated with a lower-priced generic will be a significant benefit. Manufacturers of both Orfadin and NITYR are expected to continue offering PAPs to support patients facing financial hardship. However, the reliance on such programs may decrease as the overall cost of therapy declines.
Patient Access & Reimbursement Factors:
- Payer Formulary Placement: NITYR's lower price is expected to facilitate easier formulary acceptance by private insurers and government programs.
- Prior Authorization: While nitisinone generally requires prior authorization due to its specialty nature and cost, the approval process may become smoother with a lower-cost generic available.
- Co-pays and Deductibles: Patients are likely to experience substantially lower out-of-pocket costs for nitisinone treatment with the availability of NITYR.
- Patient Assistance Programs (PAPs): Both branded and generic manufacturers will likely continue to offer PAPs, but the need for extensive financial support may diminish.
- Market Access Challenges: Despite the generic entry, access may still vary geographically and by payer, with some smaller or more restrictive plans potentially lagging in adoption.
- Physician Prescribing Patterns: Physicians will likely consider the cost-effectiveness of NITYR, especially when initiating new patients on therapy.
The long-term outlook suggests that nitisinone, in both its branded and generic forms, will remain a critical treatment for HT-1. The increased affordability brought by generic competition is poised to expand access to this life-saving therapy.
What are the Potential Future Market Developments for Nitisinone?
While the immediate future of nitisinone (NDC 16571-0411) is dominated by the dynamics of branded versus generic competition, several potential future market developments could influence its trajectory. These include the exploration of new indications, advancements in delivery methods, and ongoing regulatory scrutiny.
New Indications: Although nitisinone's primary indication is HT-1, its mechanism of action targeting HPPD has led to research into its potential efficacy in other conditions. Phenylalanine hydroxylase deficiency (PKU), another metabolic disorder, shares some downstream effects with HT-1, and nitisinone has been investigated as an adjunctive therapy or in specific patient populations. Research into other metabolic disorders or conditions where tyrosine metabolism plays a role could lead to expanded indications, thereby increasing the overall market size and demand for nitisinone.
Combination Therapies: The possibility of combining nitisinone with other therapeutic agents for HT-1 or related conditions remains an area for potential development. While nitisinone is highly effective as monotherapy, ongoing research might identify synergistic effects with other drugs, leading to novel treatment regimens. Such advancements could lead to new patentable formulations or combination products.
Delivery Method Innovations: Current nitisinone formulations are primarily oral. Future developments could include novel drug delivery systems, such as extended-release formulations or alternative routes of administration, designed to improve patient compliance, reduce dosing frequency, or enhance pharmacokinetic profiles. These innovations could potentially lead to new product launches and associated patent protection.
Manufacturing and Supply Chain Efficiencies: As the market matures and generic competition intensifies, there will be ongoing pressure to optimize manufacturing processes and supply chains to reduce costs. Companies that can achieve greater efficiency in producing nitisinone may gain a competitive advantage, particularly in the generic space.
Regulatory Scrutiny and Market Exclusivity: While nitisinone has enjoyed orphan drug exclusivity and patent protection, ongoing regulatory reviews and potential challenges to existing patents could occur. The expiry of specific patents or post-market surveillance findings could also influence market dynamics.
Global Market Expansion: Efforts to increase access to nitisinone in developing countries or regions with limited access to rare disease therapies could represent a future growth area. This would likely involve tiered pricing strategies and partnerships with local healthcare providers and governments.
The competitive landscape for nitisinone is expected to remain dynamic. While generic competition has reshaped pricing, continued research and development, coupled with evolving regulatory and healthcare environments, will shape its long-term market position.
Key Takeaways
- Nitisinone (NDC 16571-0411) is a critical orphan drug for hereditary tyrosinemia type 1 (HT-1).
- The market has transitioned from a single-branded product (Orfadin) to include a generic competitor (NITYR), significantly impacting pricing.
- NITYR's introduction is expected to reduce the annual cost of nitisinone therapy by 30-50% within five years.
- Patient access is projected to improve due to lower out-of-pocket costs and more favorable payer policies.
- Future market developments may include new indications, innovative delivery methods, and manufacturing efficiencies.
Frequently Asked Questions
-
What is the primary indication for nitisinone (NDC 16571-0411)? Nitisinone is indicated for the treatment of hereditary tyrosinemia type 1 (HT-1).
-
How has the introduction of NITYR affected the price of nitisinone? The introduction of NITYR, a generic version, has led to a significant reduction in the overall price of nitisinone, with projections indicating a 30-50% decrease in average selling price within five years.
-
Will patients experience lower out-of-pocket costs for nitisinone with the generic available? Yes, with the availability of a lower-priced generic, patients are expected to experience substantially lower co-pays and deductibles.
-
What are the main factors influencing future market developments for nitisinone? Future developments are expected to be driven by potential new indications, advancements in drug delivery systems, manufacturing efficiencies, and global market expansion.
-
Can nitisinone be used to treat other conditions besides HT-1? Research has explored nitisinone's potential in other conditions, such as phenylketonuria (PKU), but its primary approved indication remains HT-1.
More… ↓
